501-3292
Production Way, Burnaby, B.C., V5A 4R4
Phone:
(604) 551-7831 Fax: 604-676-2767
info@cannabixtechnologies.com
cannabixtechnologies.com
Cannabix
Technologies Completes
Breath Collection
Unit
and Provides
Update
The Cannabix Marijuana Breathalyzer
system
is being developed to give law enforcement and employers a tool to
enforce public safety.
Vancouver, British
Columbia -- January
28,
2019 -- InvestorsHub
NewsWire -- Cannabix Technologies Inc. (CSE: BLO) (OTC PINK: BLOZF) (the "Company or
Cannabix") developer of the
Cannabix Marijuana Breathalyzer for law enforcement and the
workplace, is pleased report that it has received an initial
version of its
portable
handheld device that will provide for easy collection of breath
samples at the point of care. In collaboration with
Company scientists, MistyWest
Engineering of
Vancouver was engaged
to
develop a breath collection
unit ("BCU") in late
November, that
would
interface
directly with the innovative FAIMS (field asymmetric
waveform ion mobility spectrometry) based instrument for the
detection of THC in human breath that Cannabix is
developing. The BCU
is a
proprietary device that will make it easier
to collect key physiologic
breath sample data under different environmental conditions
to
determine the effects of
such
parameters on a 9-tetrahydrocannabinol ("THC") breath
sample. BCU components
were
machined
and assembled over the course
of December and
January and
MistyWest
has
delivered an initial version of
the BCU. Images
of the
Cannabix BCU can be seen at the Company's
website at cannabixtechnologies.com.
Cannabix
will
use the
new BCU
for the
collection of multiple samples, from
multiple
users
under a variety of conditions, in an efficient
manner. The
BCU
is
lightweight,
runs on a conventional
battery
and
includes
a self-contained specialized breath sample container
that
integrates
directly
with the Company's FAIMS detection device for
analysis. The BCU
has
been designed to collect
numerous samples required for pilot and research testing and be
easy to administer by untrained personnel.
The
BCU
real time
data display wirelessly connects
to an android
device
for live
data streaming and
this
data can
be
sent to the cloud
for further
analysis
and storage. Currently the BCU
will collect key real-time parameters of
breath
flow
rate, total volume, relative humidity
measurements, as well as
carbon
dioxide levels, and temperature these measurements
and others, will help Cannabix,
regulators and industry
scientists
determine key
physiologic parameters
needed
for standardizing a breath sample
for
FAIMS
THC
content
and its
decay metrics. There is
currently scant
information related
to these critical
physiologic
data
points available for
human
breath in THC
smokers.
Cannabix
has been building upon its promising characterization results
from 2018
and
with additional FAIMS
cells to improve resolving
power and
establish
repeatable results in multiple devices. Thus far testing has
demonstrated the ability to isolate 9-tetrahydrocannabinol ("THC")
and suppress background substrates substantially.
FAIMS
works as an "ion blocking" technology, essentially blocking
unwanted ions/analytes and allowing specified ions to pass through
for detection. The characterization work has been conducted using
a bench version of the
FAIMS device. Cannabix scientists have been actively tuning the
FAIMS device coupled to real time switchable mass spectrometry to
detect key molecules and their complex pathways in the body to
enable the identification of recency of use.
About
Cannabix Technologies Inc.
Cannabix
Technologies Inc. is a leader in marijuana breathalyzer development
for law enforcement and the workplace. Cannabix has established
breath testing technologies in the pursuit of bringing durable,
portable hand-held tools to market to enhance detection of
marijuana impaired driving offences on roads at a time when
marijuana is becoming legal in many global jurisdictions. Cannabix
is working to develop drug-testing devices that will detect THC-
the psychoactive component of marijuana that causes intoxication-
using breath samples. In particular, Cannabix is focused on
developing breath testing devices for detection of recent use of
THC, in contrast to urine testing for THC metabolite that requires
an invasive collection and reflects usage,
days or
even weeks earlier. The devices will also be useful for other
practical applications such as testing employees in the workplace
where impairment
by THC
can be hazardous.
We seek
Safe Harbor.
On
behalf of the Board of Directors
"Rav
Mlait"
CEO
Cannabix
Technologies Inc.
For
further information, contact the Company at
info@cannabixtechnologies.com
The
CSE has not reviewed and does not accept responsibility for the
adequacy or accuracy of this release.
Cautionary Statement
Regarding Forward-Looking Statements
This
press release contains forward-looking information that involves
various risks and uncertainties regarding future events. Such
forward-looking information can include without limitation
statements based on current expectations involving a number of
risks and uncertainties and are not guarantees of future
performance of the Company, such as final development of a
commercial or prototype product(s), successful trial or pilot of
company technologies, no assurance that commercial sales of any
kind actually materialize; no assurance the Company will have
sufficient funds to complete product development. There are
numerous risks and uncertainties that could cause actual results
and the Company's plans and objectives to differ materially from
those expressed in the forward-looking information, including: (i)
adverse market conditions; (ii) risks regarding protection of
proprietary technology; (iii) the ability of the Company to
complete financings; (iv) the ability of the Company to develop and
market its future product; and (v) risks regarding government
regulation, managing and maintaining growth, the effect of adverse
publicity, litigation, competition and other factors which may be
identified from time to time in the Company's public announcements
and filings. There is no assurance that the marijuana breathalyzer
business will provide any benefit to the Company, and no assurance
that any proposed new products will be built or proceed. There is
no assurance that existing "patent pending" technologies licensed
by the Company will receive patent status by regulatory
authorities. The Company is not currently selling commercial
breathalyzers. Actual results and future events could differ
materially from those anticipated in such information. These and
all subsequent written and oral forward-looking information are
based on estimates and opinions of management on the dates they are
made and are expressly qualified in their entirety by this notice.
Except as required by law, the Company does not intend to update
these forward-looking statements.